FDA reviewing heart risks of Glaxo diabetes pill

April 12, 2013

(AP)—The Food and Drug Administration will hold a meeting in June to reassess the safety of GlaxoSmithKline's former blockbuster diabetes drug Avandia.

Avandia was severely restricted in 2010 due to concerns about its impact on the heart.

Regulators announced the highly unusual move in a government notice Friday. The FDA will ask a panel of outside experts to review a new analysis of the key study about Avandia's heart risks.

A spokeswoman for Glaxo said the drug company commissioned researchers at Duke University to reanalyze the study, and submitted the results to the FDA last year.

The FDA first approved the drug in 1999 and it became the top-selling in the world by 2006. Sales began plummeting in 2007 after researchers began questioning the drug's safety.

Explore further: US panel backs novel diabetes pill from J&J (Update)


Related Stories

US panel backs novel diabetes pill from J&J (Update)

January 10, 2013

A panel of U.S. health experts ruled Thursday that an experimental diabetes drug from Johnson & Johnson is safe and effective, though lingering safety questions must be tracked over the long term.

Recommended for you

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.